Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer. Issue 1 (2021)

Record Type:
Journal Article
Title:
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer. Issue 1 (2021)
Main Title:
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer
Authors:
Guo, Matthew Z
Marrone, Kristen A
Spira, Alexander
Freeman, Kristine
Scott, Susan C
Is Part Of:
Touch reviews in oncology & haematology. Volume 17:Issue 1(2021)
Journal:
Touch reviews in oncology & haematology
Issue:
Volume 17:Issue 1(2021)
Issue Display:
Volume 17, Issue 1 (2021)
Year:
2021
Volume:
17
Issue:
1
Issue Sort Value:
2021-0017-0001-0000
Page Start:
Page End:
Publication Date:
2021
Subjects:
Oncology -- Periodicals
Hematology -- Periodicals
616.994005
Journal URLs:
https://touchoncology.com/journals/oncology-hematology-review-us/touchreviews-in-oncology-haematology-volume-17-issue-1-2021/ ↗
DOI:
↗
Languages:
English
ISSNs:
2752-5481
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library HMNTS - ELD Digital store
Ingest File:
17194.xml